2002

25.11.2002
GENESIS AND SR PHARMA INITIATE PHASE II TRIAL OF SRP299 IN CHILDHOOD ECZEMA

17.11.2002
GENESIS RESEARCH AND CORIXA PROVIDE PVAC™ TREATMENT PROGRAM UPDATE

26.09.2002
GENESIS RESEARCH ESTABLISHES HIGH LEVEL STRATEGIC DEVELOPMENT TEAM

28.07.2002
GENESIS RESEARCH ANNOUNCES HALF YEAR RESULT

16.07.2002
GENESIS RESEARCH ANNOUNCES $6 MILLION RESEARCH GRANT

28.06.2002
GENESIS ANNOUNCES START OF CLINICAL TRIAL OF PVAC™ WITH UVB IN NEW ZEALAND

28.06.2002
GENESIS CONFIRMS FULL LISTING ON AUSTRALIAN STOCK EXCHANGE FROM 1ST JULY

07.06.2002
GENESIS ANNOUNCES NEW U.S. CLINICAL TRIAL OF PVAC™

03.05.2002
GENESIS RESEARCH ANNOUNCES RESULTS OF PHASE I SAFETY STUDY IN ATOPIC DERMATITIS

05.04.2002
GENESIS RESEARCH CONFIRMS INTENTION TO SEEK FULL ASX LISTING

27.03.2002
GENESIS APPOINTS VICE-PRESIDENT FOR PLANT SCIENCE BUSINESS DEVELOPMENT IN USA

27.03.2002
GENESIS APPOINTS VICE-PRESIDENT FOR HEALTH SCIENCE BUSINESS DEVELOPMENT IN USA

07.02.2002
GENESIS RESEARCH AND IMMUNEX CORPORATION SIGN NEW COLLABORATION AGREEMENT

31.01.2002
GENESIS RESEARCH FINISHES THE YEAR WITH $48 MILLION CASH

17.01.2002
GENESIS AND LANDCARE RESEARCH TEAM TO TACKLE “GREY MOULD” GENETICS

[Home]